QQQ   317.88 (-0.88%)
AAPL   164.20 (-0.41%)
MSFT   279.60 (-0.26%)
META   168.24 (-1.18%)
GOOGL   116.70 (-0.51%)
AMZN   137.58 (-1.31%)
TSLA   858.74 (-1.44%)
NVDA   173.36 (-2.57%)
NIO   19.87 (-1.49%)
BABA   92.77 (+2.12%)
AMD   97.40 (-2.67%)
MU   59.68 (-2.88%)
T   18.09 (+0.50%)
CGC   3.14 (-4.27%)
GE   75.40 (+0.29%)
F   15.56 (-1.39%)
DIS   108.29 (-0.75%)
AMC   23.51 (-1.88%)
PYPL   95.24 (-1.06%)
PFE   50.04 (+0.95%)
NFLX   229.34 (-1.78%)
QQQ   317.88 (-0.88%)
AAPL   164.20 (-0.41%)
MSFT   279.60 (-0.26%)
META   168.24 (-1.18%)
GOOGL   116.70 (-0.51%)
AMZN   137.58 (-1.31%)
TSLA   858.74 (-1.44%)
NVDA   173.36 (-2.57%)
NIO   19.87 (-1.49%)
BABA   92.77 (+2.12%)
AMD   97.40 (-2.67%)
MU   59.68 (-2.88%)
T   18.09 (+0.50%)
CGC   3.14 (-4.27%)
GE   75.40 (+0.29%)
F   15.56 (-1.39%)
DIS   108.29 (-0.75%)
AMC   23.51 (-1.88%)
PYPL   95.24 (-1.06%)
PFE   50.04 (+0.95%)
NFLX   229.34 (-1.78%)
QQQ   317.88 (-0.88%)
AAPL   164.20 (-0.41%)
MSFT   279.60 (-0.26%)
META   168.24 (-1.18%)
GOOGL   116.70 (-0.51%)
AMZN   137.58 (-1.31%)
TSLA   858.74 (-1.44%)
NVDA   173.36 (-2.57%)
NIO   19.87 (-1.49%)
BABA   92.77 (+2.12%)
AMD   97.40 (-2.67%)
MU   59.68 (-2.88%)
T   18.09 (+0.50%)
CGC   3.14 (-4.27%)
GE   75.40 (+0.29%)
F   15.56 (-1.39%)
DIS   108.29 (-0.75%)
AMC   23.51 (-1.88%)
PYPL   95.24 (-1.06%)
PFE   50.04 (+0.95%)
NFLX   229.34 (-1.78%)
QQQ   317.88 (-0.88%)
AAPL   164.20 (-0.41%)
MSFT   279.60 (-0.26%)
META   168.24 (-1.18%)
GOOGL   116.70 (-0.51%)
AMZN   137.58 (-1.31%)
TSLA   858.74 (-1.44%)
NVDA   173.36 (-2.57%)
NIO   19.87 (-1.49%)
BABA   92.77 (+2.12%)
AMD   97.40 (-2.67%)
MU   59.68 (-2.88%)
T   18.09 (+0.50%)
CGC   3.14 (-4.27%)
GE   75.40 (+0.29%)
F   15.56 (-1.39%)
DIS   108.29 (-0.75%)
AMC   23.51 (-1.88%)
PYPL   95.24 (-1.06%)
PFE   50.04 (+0.95%)
NFLX   229.34 (-1.78%)
NASDAQ:GBT

Global Blood Therapeutics - GBT Stock Forecast, Price & News

$66.63
+0.03 (+0.05%)
(As of 08/9/2022 09:46 AM ET)
Add
Compare
Today's Range
$66.48
$66.64
50-Day Range
$22.30
$66.60
52-Week Range
$21.65
$73.02
Volume
98,771 shs
Average Volume
2.02 million shs
Market Capitalization
$4.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.40

Global Blood Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
4.5% Downside
$63.58 Price Target
Short Interest
Healthy
14.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.28mentions of Global Blood Therapeutics in the last 14 days
Based on 42 Articles This Week
Insider Trading
Selling Shares
$34,335 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.65) to ($3.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

779th out of 1,098 stocks

Pharmaceutical Preparations Industry

383rd out of 536 stocks

GBT stock logo

About Global Blood Therapeutics (NASDAQ:GBT) Stock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GBT shares. Stifel Nicolaus reiterated a "hold" rating on shares of Global Blood Therapeutics in a report on Monday. Canaccord Genuity Group upgraded shares of Global Blood Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the company from $40.00 to $72.00 in a research note on Monday. Canaccord Genuity Group upgraded Global Blood Therapeutics from a "hold" rating to a "buy" rating and upped their price objective for the company from $40.00 to $72.00 in a research report on Monday. Wedbush restated a "neutral" rating on shares of Global Blood Therapeutics in a research note on Monday. Finally, StockNews.com raised shares of Global Blood Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 5th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Global Blood Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $63.17.

Global Blood Therapeutics Price Performance

GBT Stock traded up $2.80 during trading on Monday, hitting $66.64. The stock had a trading volume of 2,137,513 shares, compared to its average volume of 1,436,550. The company's 50-day moving average price is $31.23 and its two-hundred day moving average price is $30.80. The company has a debt-to-equity ratio of 4.34, a current ratio of 8.52 and a quick ratio of 7.74. The stock has a market capitalization of $4.34 billion, a P/E ratio of -13.68 and a beta of 0.83. Global Blood Therapeutics has a twelve month low of $21.65 and a twelve month high of $73.02.

Insiders Place Their Bets

In related news, Director Philip A. Pizzo sold 1,260 shares of the business's stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $27.25, for a total transaction of $34,335.00. Following the completion of the transaction, the director now directly owns 9,112 shares of the company's stock, valued at approximately $248,302. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.90% of the stock is owned by insiders.

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Stock News Headlines

Pfizer buying spree continues with $5.4B hematology deal
Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic
Pfizer buying spree continues with $5.4B hematology deal
Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic
See More Headlines
Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Company Calendar

Last Earnings
8/08/2022
Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GBT
Fax
N/A
Employees
457
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$63.58
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
-7.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$-303,090,000.00
Net Margins
-146.82%
Pretax Margin
-146.57%

Debt

Sales & Book Value

Annual Sales
$194.75 million
Book Value
$3.05 per share

Miscellaneous

Free Float
61,908,000
Market Cap
$4.34 billion
Optionable
Optionable
Beta
0.83

Key Executives

  • Dr. Ted W. Love M.D. (Age 63)
    Pres, CEO & Director
    Comp: $1.06M
  • Mr. Jeffrey S. Farrow (Age 60)
    CFO & Principal Accounting Officer
    Comp: $672.67k
  • Ms. Jung E. Choi (Age 52)
    Chief Bus. & Strategy Officer
    Comp: $645k
  • Mr. David L. Johnson (Age 53)
    Chief Commercial Officer
    Comp: $661.5k
  • Dr. Kim Smith-Whitley M.D. (Age 61)
    Exec. VP and Head of R&D
    Comp: $654k
  • Dr. David R. Phillips
    Founder & Advisor
  • Dr. Matthew P. Jacobson Ph.D.
    Founder & Advisor
  • Dr. Andrej Sali Ph.D.
    Founder & Advisor
  • Ms. Nazila Habibizad (Age 59)
    Exec. VP of Operations
  • Stephanie Yao
    Sr. Director of Corp. Communications & Investor Relations













GBT Stock - Frequently Asked Questions

Should I buy or sell Global Blood Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GBT shares.
View GBT analyst ratings
or view top-rated stocks.

What is Global Blood Therapeutics' stock price forecast for 2022?

12 analysts have issued twelve-month price objectives for Global Blood Therapeutics' shares. Their GBT share price forecasts range from $31.00 to $75.00. On average, they expect the company's stock price to reach $63.17 in the next twelve months. This suggests that the stock has a possible downside of 5.2%.
View analysts price targets for GBT
or view top-rated stocks among Wall Street analysts.

How has Global Blood Therapeutics' stock price performed in 2022?

Global Blood Therapeutics' stock was trading at $29.27 at the beginning of the year. Since then, GBT shares have increased by 127.5% and is now trading at $66.60.
View the best growth stocks for 2022 here
.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our GBT earnings forecast
.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its earnings results on Thursday, November, 4th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.03. The company had revenue of $52.05 million for the quarter, compared to analysts' expectations of $53.69 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 129.74% and a negative net margin of 146.82%. The firm's revenue was up 41.1% compared to the same quarter last year. During the same period last year, the company earned ($0.97) earnings per share.

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

13 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Roosevelt Investment Group LLC (1.23%), Candriam S.C.A. (1.20%), EULAV Asset Management (0.58%), Rice Hall James & Associates LLC (0.36%), Mizuho Markets Americas LLC (0.29%) and Assenagon Asset Management S.A. (0.26%). Insiders that own company stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends
.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $66.60.

How much money does Global Blood Therapeutics make?

Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $4.34 billion and generates $194.75 million in revenue each year. The company earns $-303,090,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis.

How many employees does Global Blood Therapeutics have?

Global Blood Therapeutics employs 457 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at investor@gbt.com.

This page (NASDAQ:GBT) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.